Oryzon Genomics S.A.
Healthcare · EUR · BME
Price
€3.116
Cap
€104.28M
Earnings
—
30d Trend
+13.2%
33% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 48×Macro 0.99 (−1%)=48
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
5-10 day swing — momentum continuation
BRAIN47'S ASSESSMENT
I rate Oryzon Genomics S.A. at 48/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is technical at 58/100. I classify this as a growth position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
+13.3%
3 MONTHS
-0.8%
12 MONTHS
+15.1%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
5-10 day swing — momentum continuation. Technical (58) and Quality (51) are the primary strengths. I note that fundamentals is the weakest area at 20/100 — this warrants monitoring. Historical volatility is moderate at 33%. I classify this as a growth position — positive trend direction combined with growth potential points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.